Related Experiment Video

Updated: Nov 4, 2025

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.3K

The current understanding on the impact of KRAS on colorectal cancer

Mingjing Meng1, Keying Zhong1, Ting Jiang1

  • 1Guangdong Key Laboratory for Translational Cancer Research of Chinese Medicine, Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, School of Pharmaceutical Science, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|May 27, 2021
PubMed

Insights

KRAS mutations significantly impact colorectal cancer (CRC) prognosis and treatment. This review details their pathological roles, effects on chemotherapy response, and current therapeutic strategies for KRAS-mutant CRC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • KRAS (kirsten rat sarcoma viral oncogene) mutations are prevalent in colorectal cancer (CRC).
  • These mutations influence patient prognosis and survival rates.
  • Targeted therapies for KRAS-mutant CRC are an active area of research.

Purpose of the Study:

  • To review the pathological consequences of KRAS mutations in CRC development.
  • To analyze the impact of KRAS mutations on chemotherapy response and sensitivity.
  • To discuss current therapeutic strategies, challenges, and future directions for KRAS-mutant CRC.

Main Methods:

  • Literature review of current research on KRAS mutations in colorectal cancer.
  • Analysis of pathological roles and clinical implications of KRAS mutations.
  • Synthesis of information on therapeutic strategies and treatment challenges.

Main Results:

  • KRAS mutations play a critical role in CRC pathogenesis.
  • These mutations affect patient response to standard chemotherapies.
  • Understanding these impacts is crucial for developing effective treatments.

Conclusions:

  • KRAS mutations are key drivers in colorectal cancer development and progression.
  • Targeting KRAS mutations presents unique challenges in clinical practice.
  • Further research is needed to overcome therapeutic resistance and improve outcomes for CRC patients with KRAS mutations.
Keywords:
Colorectal cancerKRASMutationTherapy

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.0K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

475

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.6K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.8K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.5K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.3K